Skip to content
10-Q/A

Quarterly Report

BIOREGENX, INC. BRGX

0001683168-24-007021

← back to feed
Filed
Oct 9, 2024 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Sep 18, 2024 956.53M sh
Shares Diluted restated Q1 2024 · Mar 31, 2024 767.6M sh
Shares Diluted restated Q1 2024 · Mar 31, 2023 618.97M sh
Capex restated Q1 2024 · Mar 31, 2024 $189.39K
Capex Q1 2024 · Mar 31, 2023 $0
Operating Cash Flow restated Q1 2024 · Mar 31, 2024 −$104.25K
Operating Cash Flow restated Q1 2024 · Mar 31, 2023 −$336.79K
Cash And Equivalents Q1 2024 · Mar 31, 2024 $114.16K
Cash And Equivalents Q1 2024 · Dec 31, 2023 $125.4K
Stockholders Equity restated Q1 2024 · Mar 31, 2024 $15.09M
Stockholders Equity restated Q1 2024 · Dec 31, 2023 −$2.07M
Stockholders Equity restated Q1 2024 · Mar 31, 2023 −$2.42M
Stockholders Equity restated Q1 2024 · Dec 31, 2022 −$2.53M
Current Liabilities restated Q1 2024 · Mar 31, 2024 $3.38M
Current Liabilities restated Q1 2024 · Dec 31, 2023 $2.79M
Total Liabilities restated Q1 2024 · Mar 31, 2024 $3.53M
Total Liabilities restated Q1 2024 · Dec 31, 2023 $2.94M
Current Assets restated Q1 2024 · Mar 31, 2024 $485.46K
Current Assets restated Q1 2024 · Dec 31, 2023 $652.66K
Total Assets restated Q1 2024 · Mar 31, 2024 $18.62M
Total Assets restated Q1 2024 · Dec 31, 2023 $865.75K
Eps Diluted Q1 2024 · Mar 31, 2024 $0.00
Eps Diluted Q1 2024 · Mar 31, 2023 $0.00
Eps Basic Q1 2024 · Mar 31, 2024 $0.00
Eps Basic Q1 2024 · Mar 31, 2023 $0.00
Sga Expense restated Q1 2024 · Mar 31, 2024 $2.91M
Sga Expense Q1 2024 · Mar 31, 2023 $770.99K
Rd Expense Q1 2024 · Mar 31, 2024 $25.54K
Rd Expense Q1 2024 · Mar 31, 2023 $80.78K
Net Income restated Q1 2024 · Mar 31, 2024 −$3.15M
Net Income restated Q1 2024 · Mar 31, 2023 −$229.84K
Operating Income restated Q1 2024 · Mar 31, 2024 −$3.08M
Operating Income restated Q1 2024 · Mar 31, 2023 −$184.11K
Gross Profit restated Q1 2024 · Mar 31, 2024 $384.16K
Gross Profit Q1 2024 · Mar 31, 2023 $763.89K
Cost Of Revenue restated Q1 2024 · Mar 31, 2024 $165.39K
Cost Of Revenue Q1 2024 · Mar 31, 2023 $311.69K
Revenue restated Q1 2024 · Mar 31, 2024 $549.55K
Revenue restated Q1 2024 · Mar 31, 2023 $1.08M